Technical Analysis for TGTX - TG Therapeutics, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Down |
| See historical TGTX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Bullish Engulfing | Bullish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 2.18% | |
| Wide Bands | Range Expansion | 2.18% | |
| Down 3 Days in a Row | Weakness | 2.18% | |
| 20 DMA Resistance | Bearish | 1.14% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 1.14% | |
| NR7 | Range Contraction | 1.14% | |
| Inside Day | Range Contraction | 1.14% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/14/2019
- Sector: Healthcare
- Industry: Biotechnology
TG Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The company is developing two advanced therapies targeting hematological malignancies. The TGTX-1101 (ublituximab) is a novel, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes, which is in clinical development for patients with relapsed and refractory non-Hodgkin's lymphoma. The TGR-1202 is an orally available PI3K delta inhibitor believed to be important in the proliferation and survival of B-lymphocytes. TG Therapeutics, Inc. is headquartered in New York, New York.
Biopharmaceutical Cancer Treatment Of Cancer Monoclonal Antibodies Lymphoma Antibody Drug Conjugates Hematological Malignancies Camidanlumab Tesirine Cd20
Biopharmaceutical Cancer Treatment Of Cancer Monoclonal Antibodies Lymphoma Antibody Drug Conjugates Hematological Malignancies Camidanlumab Tesirine Cd20
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more TGTX news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 12.9 |
| 52 Week Low | 3.32 |
| Average Volume | 1,509,772 |
| 200-Day Moving Average | 6.1325 |
| 50-Day Moving Average | 7.4582 |
| 20-Day Moving Average | 7.972 |
| 10-Day Moving Average | 8.078 |
| Average True Range | 0.416 |
| ADX | 20.11 |
| +DI | 21.5374 |
| -DI | 19.2098 |
| Chandelier Exit (Long, 3 ATRs ) | 8.132000000000001 |
| Chandelier Exit (Short, 3 ATRs ) | 8.058 |
| Upper Bollinger Band | 9.2292 |
| Lower Bollinger Band | 6.7148 |
| Percent B (%b) | 0.5 |
| BandWidth | 31.540391 |
| MACD Line | 0.1421 |
| MACD Signal Line | 0.215 |
| MACD Histogram | -0.0729 |
| Fundamentals | Value |
|---|---|
| Market Cap | 496.61 Million |
| Num Shares | 62.3 Million |
| EPS | -1.95 |
| Price-to-Earnings (P/E) Ratio | -4.09 |
| Price-to-Sales | 3189.49 |
| Price-to-Book | 6.24 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 8.44 | ||||
| Resistance 3 (R3) | 8.39 | 8.18 | 8.36 | ||
| Resistance 2 (R2) | 8.18 | 8.06 | 8.21 | 8.33 | |
| Resistance 1 (R1) | 8.08 | 7.99 | 8.13 | 8.13 | 8.31 |
| Pivot Point | 7.87 | 7.87 | 7.90 | 7.90 | 7.87 |
| Support 1 (S1) | 7.77 | 7.75 | 7.82 | 7.82 | 7.63 |
| Support 2 (S2) | 7.56 | 7.68 | 7.59 | 7.61 | |
| Support 3 (S3) | 7.46 | 7.56 | 7.58 | ||
| Support 4 (S4) | 7.51 |
